Vinay Prasad Ouster Sparks Industry Concerns and Implications
The sudden ouster of FDA official Vinay Prasad from his role running the agency’s biologics division has sparked controversy in the biotech industry. This move comes after a series of decisions on Sarepta’s gene therapy for Duchenne muscular dystrophy, which were met with criticism from conservative voices. To discuss the implications of this development, we … Read more